174 related articles for article (PubMed ID: 12203031)
1. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders.
Juji T; Hertz M; Aoki K; Horie D; Ohya K; Gautam A; Mouritsen S; Oda H; Nakamura K; Tanaka S
J Bone Miner Metab; 2002; 20(5):266-8. PubMed ID: 12203031
[No Abstract] [Full Text] [Related]
2. [OPG, anti-rANKL antibody].
Yasuda H
Nihon Rinsho; 2005 Sep; 63(9):1647-53. PubMed ID: 16164225
[TBL] [Abstract][Full Text] [Related]
3. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
4. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
6. [A novel therapeutic vaccine approach against RANKL that prevents pathological bone destruction].
Tanaka S
Clin Calcium; 2005 Jul; 15(7):62-6. PubMed ID: 15995298
[TBL] [Abstract][Full Text] [Related]
7. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
Kostenuik PJ
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
[No Abstract] [Full Text] [Related]
9. [[From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin?].
Bénard J
Bull Cancer; 2000 Sep; 87(9):623-4. PubMed ID: 11184451
[No Abstract] [Full Text] [Related]
10. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
[No Abstract] [Full Text] [Related]
11. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
Ashcroft AJ; Carding SR
Gut; 2005 Sep; 54(9):1345-6. PubMed ID: 16099805
[No Abstract] [Full Text] [Related]
12. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
13. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
[TBL] [Abstract][Full Text] [Related]
14. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
15. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
16. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
17. [Novel therapeutic approach to bone metabolic disorders using RANKL vaccination].
Juji T; Tanaka S
Nihon Rinsho; 2004 Feb; 62 Suppl 2():799-802. PubMed ID: 15035230
[No Abstract] [Full Text] [Related]
18. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
19. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
20. Interactions between immune and bone cells: new insights with many remaining questions.
Lorenzo J
J Clin Invest; 2000 Sep; 106(6):749-52. PubMed ID: 10995785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
